Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

Leuk Lymphoma. 2020 Jul;61(7):1756-1759. doi: 10.1080/10428194.2020.1737689. Epub 2020 Mar 19.

Authors

Isolde Summerer¹, Claudia Haferlach¹, Manja Meggendorfer¹, Wolfgang Kern¹, Torsten Haferlach¹, Anna Stengel¹

Affiliation

¹ MLL Munich Leukemia Laboratory, Munich, Germany.

PMID: 32189545
DOI: 10.1080/10428194.2020.1737689

No abstract available

Publication types

Letter

MeSH terms

Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
MDS1 and EVI1 Complex Locus Protein
Mutation
Prognosis
Proto-Oncogenes
Transcription Factors* / genetics

Substances

MDS1 and EVI1 Complex Locus Protein
MECOM protein, human
Transcription Factors